|Intercept Pharmaceuticals, Inc.|
18 Desbrosses Street
United States - Map
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
|Intercept Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2013 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Mark Pruzanski M.D.,
Founder, Chief Exec. Officer, Pres and Director
|Ms. Barbara Duncan ,
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
|Mr. David Shapiro M.D., Ph.D.,
Chief Medical Officer and Exec. VP of Devel.
|Dr. Luciano Adorini M.D.,
Chief Scientific Officer
|Dr. Roberto Pellicciari Ph.D.,
Head of Medicinal Chemistry and Member of the Scientific Advisory Board
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|